Safety and efficacy of first-line pembrolizumab in patients with non-small cell lung cancer: A multicenter retrospective study
Latest Information Update: 08 Mar 2021
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer